A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial


Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
To assess the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system (LNG-IUS) (Mirena®, Bayer) compared with usual medical treatment, with exploration of women's perspectives on treatment.

Authors' conclusions
The LNG-IUS, compared with usual medical therapies, resulted in greater improvement over 2 years in women's assessments of the effect of HMB on their daily routine, including work, social and family life, and psychological and physical well-being. At 5 years, the differences were no longer significant. A similar low proportion of women required surgical intervention in both groups. The LNG-IUS is cost-effective in both the short and medium term, using the method generally recommended by the National Institute for Health and Care Excellence. Using the alternative measures to value QoL will have a considerable impact on cost-effectiveness decisions. It will be important to explore the clinical and health-care trajectories of the ECLIPSE (clinical effectiveness and cost-effectiveness of levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia) trial participants to 10 years, by which time half of the cohort will have reached menopause.

Project page URL
http://www.nets.nihr.ac.uk/projects/hta/020602

Final publication URL
http://www.journalslibrary.nihr.ac.uk/hta/hta19880/#/abstract

Indexing Status
Subject indexing assigned by CRD

MeSH
Contraceptive Agents, Female /administration & dosage /economics; Cost-Benefit Analysis; Endometriosis /drug therapy; Female; Hormone Replacement Therapy /methods; Intrauterine Devices, Medicated; Leiomyoma /drug therapy; Levonorgestrel /administration & dosage /economics; Premenstrual Syndrome /drug therapy; Uterine Hemorrhage /drug therapy

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk

AccessionNumber
32005000952

Date bibliographic record published
20/08/2005

Date abstract record published
20/08/2005